Haggerty HG[au] - Search Results

Year	Number of Results
1988	1
1989	1
1990	2
1993	1
1994	1
1997	1
1999	1
2005	1
2007	3
2008	1
2012	2
2013	2
2014	1
2018	2
2020	1
2021	1
2022	0

1

Immunomodulation and lymphoma in humans.

Ponce RA, Gelzleichter T, Haggerty HG, Heidel S, Holdren MS, Lebrec H, Mellon RD, Pallardy M. Ponce RA, et al. Among authors: haggerty hg. J Immunotoxicol. 2014 Jan-Mar;11(1):1-12. doi: 10.3109/1547691X.2013.798388. Epub 2013 Jun 7. J Immunotoxicol. 2014. PMID: 23746314 Review.

2

Cancer Immunotherapy: Factors Important for the Evaluation of Safety in Nonclinical Studies.

Herzyk DJ, Haggerty HG. Herzyk DJ, et al. Among authors: haggerty hg. AAPS J. 2018 Feb 7;20(2):28. doi: 10.1208/s12248-017-0184-3. AAPS J. 2018. PMID: 29417397 Review.

3

Thymic Lymphomas in a 6-Month rasH2-Tg Mouse Carcinogenicity Study With the RORγt Inverse Agonist, BMS-986251.

Haggerty HG, Sathish JG, Gleason CR, Al-Haddawi M, Brodie TA, Bonnette KL, Lewis BS, Graziano MJ. Haggerty HG, et al. Toxicol Sci. 2021 Aug 30;183(1):93-104. doi: 10.1093/toxsci/kfab086. Toxicol Sci. 2021. PMID: 34240189

4

BR96 sFv-PE40 immunotoxin: nonclinical safety assessment.

Haggerty HG, Warner WA, Comereski CR, Peden WM, Mezza LE, Damle BD, Siegall CB, Davidson TJ. Haggerty HG, et al. Toxicol Pathol. 1999 Jan-Feb;27(1):87-94. doi: 10.1177/019262339902700116. Toxicol Pathol. 1999. PMID: 10367679 Review.

5

Role of metabolism in dimethylnitrosamine-induced immunosuppression: a review.

Haggerty HG, Holsapple MP. Haggerty HG, et al. Toxicology. 1990 Jul;63(1):1-23. doi: 10.1016/0300-483x(90)90064-n. Toxicology. 1990. PMID: 2200161 Review.

6

Decreased immune response in monkeys administered a human T-effector cell agonist (OX40) antibody.

Gamse JT, Freebern W, Haynes Ii R, Simutis F, Pazian M, Crona J, Haggerty HG, Graziano M, Bunch RT. Gamse JT, et al. Among authors: haggerty hg. Toxicol Appl Pharmacol. 2020 Dec 15;409:115285. doi: 10.1016/j.taap.2020.115285. Epub 2020 Oct 15. Toxicol Appl Pharmacol. 2020. PMID: 33069749 Free article.

7

Immunotoxicity testing in non-rodent species.

Haggerty HG. Haggerty HG. J Immunotoxicol. 2007 Apr;4(2):165-9. doi: 10.1080/15476910701337241. J Immunotoxicol. 2007. PMID: 18958726

8

Bioavailability of protein therapeutics in rats following inhalation exposure: Relevance to occupational exposure limit calculations.

Gould JC, Carvajal I, Davidson T, Graham J, Hillegass J, Julien S, Kozhich A, Wang B, Wei H, Yamniuk AP, Mathias N, Haggerty HG, Graziano M. Gould JC, et al. Among authors: haggerty hg. Regul Toxicol Pharmacol. 2018 Dec;100:35-44. doi: 10.1016/j.yrtph.2018.10.003. Epub 2018 Oct 3. Regul Toxicol Pharmacol. 2018. PMID: 30291877

9

Chronic administration of belatacept, a T-cell costimulatory signal blocker, in cynomolgus monkeys.

Haggerty HG, Proctor SJ. Haggerty HG, et al. Toxicol Sci. 2012 May;127(1):159-68. doi: 10.1093/toxsci/kfs081. Epub 2012 Feb 13. Toxicol Sci. 2012. PMID: 22331490

10

Nonclinical aspects of biopharmaceutical development: discussion of case studies at a PhRMA-FDA workshop.

Buckley LA, Benson K, Davis-Bruno K, Dempster M, Finch GL, Harlow P, Haggerty HG, Hart T, Kinter L, Leighton JK, McNulty J, Roskos L, Saber H, Stauber A, Tabrizi M. Buckley LA, et al. Among authors: haggerty hg. Int J Toxicol. 2008 Jul-Aug;27(4):303-12. doi: 10.1080/10915810802367016. Int J Toxicol. 2008. PMID: 18821393

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results